CYP3A4 and melanoma: Overall, in adult participants with BRAF V600-mutant advanced melanoma or other solid tumors, daily doses of encorafenib in combination with binimetinib were generally safe and well-tolerated when co-administered with daily doses of CYP3A inducer modafinil.